Kura Oncology's Ziftomenib Combo Shows 94% 12-Month OS in Newly Diagnosed AML
KURA sits 62% above its 52-week low of $5.45.
Summary
Kura Oncology announced compelling long-term Phase 1/2 results for its drug ziftomenib combined with 7+3 chemotherapy in newly diagnosed AML. The data showed a 94% 12-month overall survival rate and 96% complete remission rate in NPM1-m AML patients, significantly outperforming historical standard-of-care benchmarks. While ziftomenib (KOMZIFTI) is already approved for relapsed/refractory AML, these results support its potential expansion into the newly diagnosed setting, which would be a major market opportunity. The strong data bolsters the ongoing Phase 3 registrational study. Kura will host an investor event tomorrow, June 12, to discuss these findings.
At the time of this announcement, KURA was trading at $8.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $770.6M. The 52-week trading range was $5.45 to $12.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.